Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $1.81 USD
Change Today +0.01 / 0.56%
Volume 101.2K
ARQL On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 2:33 PM 05/29/15 All times are local (Market data is delayed by at least 15 minutes).

arqule inc (ARQL) Key Developments

ArQule Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

ArQule Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, research and development revenue was $2.785 million against $2.676 million a year ago. Loss from operations was $4.815785 million against $7.305 million a year ago. Net loss was $4.551 million or $0.07 per basic and diluted share against $7.141 million or $0.11 per basic and diluted share a year ago. The revenue increase is primarily due to lower contra-revenue from Daiichi Sankyo tivantinib program.

ArQule Inc. and Beryllium Discovery Corp. Announce Collaborative Research and Development Agreement

ArQule Inc. and Beryllium Discovery Corp. announced a collaborative research and development agreement to identify and unlock the therapeutic potential of small molecule compounds by combining ArQule’s chemistry and drug development expertise with Beryllium’s discovery platforms. The Beryllium platforms integrate structure-guided drug discovery, biophysics and cell biology. The therapeutic targets to be pursued by the parties include PD-1 (programmed cell death protein 1) and PDL-1 (programmed death ligand 1), two proteins believed to play major roles in suppressing or limiting the response of the immune system. Molecules that bind to and inhibit the effects of these targets may help direct the immune system to combat a variety of tumors.

ArQule Inc. to Report Q1, 2015 Results on May 06, 2015

ArQule Inc. announced that they will report Q1, 2015 results at 9:00 AM, US Eastern Standard Time on May 06, 2015

ArQule Inc., Q1 2015 Earnings Call, May 06, 2015

ArQule Inc., Q1 2015 Earnings Call, May 06, 2015

ArQule Inc., Annual General Meeting, May 11, 2015

ArQule Inc., Annual General Meeting, May 11, 2015., at 14:00 Eastern Daylight. Location: Hyatt House, 2 Van De Graaff Drive. Agenda: To elect Timothy C. Barabe and Paolo Pucci as directors to hold office for a term of three years and until their respective successors are elected and qualified; to ratify the selection of PricewaterhouseCoopers LLP as independent registered public accounting firm for the year ending December 31, 2015; to approve, by non-binding vote, the compensation of named executive officers; and to transact any other business that may properly come before the meeting or any adjournment of the meeting.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ARQL:US $1.81 USD +0.01

ARQL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AVEO Pharmaceuticals Inc $2.05 USD +0.0501
CrystalGenomics Inc 13,450 KRW -250.00
Curis Inc $3.34 USD +0.09
Cytokinetics Inc $6.41 USD +0.1502
Rigel Pharmaceuticals Inc $3.49 USD +0.04
View Industry Companies
 

Industry Analysis

ARQL

Industry Average

Valuation ARQL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 9.8x
Price/Book 3.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 5.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ARQULE INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.